DESONIDE
Clinical safety rating: safe
Animal studies have demonstrated safety
Desonide is a synthetic corticosteroid that binds to glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, and suppress inflammatory mediators like cytokines, leading to anti-inflammatory, antipruritic, and vasoconstrictive effects.
| Metabolism | Desonide is metabolized primarily in the liver via ester hydrolysis to inactive metabolites. Minimal cytochrome P450 involvement. |
| Excretion | Renal (approximately 75% as metabolites, <10% unchanged); biliary/fecal (25%) |
| Half-life | Terminal elimination half-life is 2-3 hours in adults, consistent with short glucocorticoid activity; prolonged in hepatic impairment. |
| Protein binding | ~90% bound to albumin and corticosteroid-binding globulin (CBG). |
| Volume of Distribution | Approximately 0.5 L/kg, indicating distribution into total body water. |
| Bioavailability | Topical: unknown due to variable percutaneous absorption (approx. 1-5% of dose depending on skin condition); not formulated for oral systemic use; no IV formulation. |
| Onset of Action | Topical: 1-2 hours for vasoconstriction; oral (systemic): 2-4 hours for adrenal suppression; not available IV. |
| Duration of Action | Topical: 12-24 hours with once-daily application; systemic effects last 12-36 hours; duration shorter than betamethasone due to lower potency. |
| Molecular Weight | 416.5 |
Topical: Apply a thin film to affected area 2-3 times daily; maximum 2 weeks of continuous therapy. Intralesional: Not applicable for desonide. Ophthalmic: Not indicated.
| Dosage form | LOTION |
| Renal impairment | No dose adjustment required for topical use. Systemic exposure is minimal. |
| Liver impairment | No dose adjustment required for topical use. Systemic exposure is minimal. |
| Pediatric use | Topical: Apply a thin film to affected area 1-2 times daily for up to 2 weeks. Use lowest potency and shortest duration due to increased systemic absorption risk. Avoid occlusion. |
| Geriatric use | Use with caution due to thinner skin and increased systemic absorption risk. Apply sparingly to limited areas, avoid prolonged use. |
| 1st trimester | Topical corticosteroids are generally avoided in first trimester due to potential risk of orofacial clefts. Use only if potential benefit justifies risk. |
| 2nd trimester | May be used topically with caution. Systemic absorption is low with short-term use on small areas. |
| 3rd trimester | May be used topically with caution. Avoid prolonged use or large areas due to potential fetal growth restriction. |
Clinical note
No significant drug interactions Systemic absorption can occur with extensive use.
| Placental transfer | Minimal placental transfer after topical application. Systemic absorption is low (<1% of applied dose). |
| Breastfeeding | Topical application on small areas is unlikely to result in clinically relevant systemic concentrations. Avoid application to breasts or nipples. Monitor infant for skin irritation or adrenal suppression. |
■ FDA Black Box Warning
No FDA black box warning.
| Common Effects | Skin atrophy |
| Serious Effects |
Hypersensitivity to desonide or any componentUntreated bacterial, fungal, or viral skin infectionsPerioral dermatitisRosacea
| Precautions | Topical corticosteroids may cause reversible HPA axis suppression, especially with prolonged use or large body surface area application., Potential for local adverse effects including skin atrophy, striae, telangiectasias, and secondary infections., Systemic absorption may lead to Cushing's syndrome, hyperglycemia, and glucosuria., Use with caution in pediatric patients due to increased susceptibility to HPA suppression., Avoid occlusive dressings unless directed. |
| Food/Dietary | No known food interactions. Take as directed without regard to meals. |
Loading safety data…
| Lactation Rating | L2: Probably Compatible |
| Teratogenic Risk | Desonide is a corticosteroid; systemic absorption is minimal with topical use. Animal studies have shown teratogenic effects with high systemic doses. In humans, no adequate studies exist. First trimester: unlikely significant risk with topical use. Second and third trimesters: minimal risk but avoid chronic high-dose application. Use only if clearly needed. |
| Fetal Monitoring | Monitor for maternal skin thinning or adrenal suppression if used extensively. No specific fetal monitoring required; assess fetal growth if used chronically over large areas. |
| Fertility Effects | No studies on fertility effects in humans. Animal studies at high systemic doses showed impaired fertility; topical use is unlikely to cause effects. |
| Clinical Pearls | Desonide is a low-potency topical corticosteroid (class VI), suitable for use on face, intertriginous areas, and in pediatric patients. Avoid prolonged use in diaper area due to occlusive effect. Limit use to 2 weeks continuous unless under close supervision. Do not use with occlusive dressings unless directed. |
| Patient Advice | Apply a thin film to affected skin only, avoiding healthy skin. · Use no longer than prescribed; overuse can cause skin thinning and systemic absorption. · Do not cover the area with bandages or wraps unless instructed by your doctor. · Wash hands after application unless treating hands. · Avoid contact with eyes, mouth, and open wounds. · Stop use and notify your doctor if irritation, infection, or worsening occurs. |